Institut Universitaire Du Cancer Toulouse-Oncopole — Clinical Trial Site

23 Registered trials

7 Currently recruiting

Organisation

Institut Universitaire Du Cancer Toulouse-Oncopole

Location

Toulouse Cedex 9, France

Identifier

ORG-100023339

Address

1 Avenue Irene Joliot Curie, 31059, France

Departments

2004:Service d’Hématologie
Hematology
Hematology Departmen
Internal Medicine and Clinical Immunopathology
Medical Oncology
N/A
Onco-dermatologie
oncologie
Oncologie Médicale
Oncopole
Oncopole_ Service Hématologie
Service d'Hematologie
Service d'Oncologie Medicale
Service d’Oncologie Médicale

Clinical trials at this site (23)

Search interface

A phase II study evaluating the efficacy and safety of IMetelstat in Patients with HR myElodysplastic SyndromeS or AML failing HMA-based the… Not authorised

2022-500721-32-00 AML and MDS patients failing or being refractory to hyp 4
Clinical trial of MK-7648A in adults and children with skin cancer Not authorised

2022-501417-31-00 High-risk Resected Melanoma 5
A Phase 3b study to learn more about the safety and tolerability of ivosidenib in combination with azacitidine in adult patients newly diagn… Recruiting

2022-501709-11-00 Isocitrate deshydrogenase1 mutation-positive (IDH1m) ac 5 2023-06-06
Iberdomide Manteinance Versus Lenalidomide Manteinance Therapy Following Autologous Stem Cell Transplant in Participants with NDMM Recruiting

2022-501515-14-00 Newly Diagnosed Multiple Myeloma (NDMM) 5 2023-09-29
FLUCLORIC - Randomized multicentric Phase III study comparing the efficacy of two reduced intensity conditioning regimens (clofarabine/busul… Recruiting

2022-502019-12-00 acute myeloid leukemia 5 2023-09-14
A multi-center randomized, double blinded phase IIb trial evaluating oral pooled fecal microbiotherapy MaaT033 to prevent allogeneic hematop… Recruiting

2022-501831-18-00 Patients with hematologic malignancies and undergoing a 4 2023-09-13
Tebentafusp Regimen Versus Investigator’s Choice in Previously Treated Advanced Melanoma (TEBE-AM) Recruiting

2022-502732-39-00 Previously treated non-ocular advanced melanoma 10 2023-09-01
A trial to test if different amounts of KTX-1001 are safe and tolerable in people with the bone marrow cancer multiple myeloma that has come… Recruiting

2022-500801-41-00 Relapsed and Refractory Multiple Myeloma 1 2023-07-26
A prospective program aiming at improving outcome for young adults with poor-prognosis non seminomatous germ-cell tumors (VAPOR (GETUG T06)) Recruiting

2023-505040-19-00 Non-seminomatous germ-cell tumors (including testis, re 4 2023-04-11
A Study to Compare the Efficacy and Safety of Idecabtagene Vicleucel with Lenalidomide Maintenance Therapy Versus Lenalidomide Maintenance T… Ended

2022-501346-30-00 Newly Diagnosed Multiple Myeloma with Suboptimal Respon 5 2023-09-25
A Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Versus Alpelisib Plus Fulvestrant in Patients with Hormone Recepto… Ended

2022-502322-41-00 Metastatic breast cancer 5 2023-09-12
A study to evaluate the dose optimization measures and safety of Etentamig (ABBV-383) in subjects with Relapsed or Refractory Multiple Myelo… Ended

2023-504674-38-00 Relapsed or Refractory Multiple Myeloma 3 2023-07-31
A phase II study evaluating the efficacy and safety of IMetelstat in Patients with HR myElodysplastic SyndromeS or AML failing HMA-based the… Ended

2022-500721-32-01 AML and MDS patients failing or being refractory to hyp 4 2023-05-03
A Phase 3 study to see the benefit and safety of Luspatercept in comparison with Epoetin Alfa to treat anaemia due to very low, low or inter… Ended

2022-501485-22-00 Myelodysplastic syndrome (MDS) 5 2018-12-18
PhII Trial of Pembrolizumab in Advanced Solid Tumors Ended

2022-501253-37-00 (A) Anal Squamous Cell Carcinoma, (B) Biliary Adenocarc 4 2016-02-02
A multicenter, single arm, open-label trial to evaluate efficacy and safety of oral, twice daily iptacopan in adult PNH patients who have Hb… Ended

2022-502148-10-00 Paroxysmal Nocturnal Hemoglobinuria (PNH) 5 2023-10-10
A Phase 2, Open-Label, Multicenter, Basket Study Evaluating the Safety and Efficacy of Brexucabtagene Autoleucel in Adults with Rare B-cell … Ended

2022-501259-10-00 Relapsed/Refractory Waldenstrom Macroglobulinemia (WM) 4 2023-04-14
A Phase 2, Open-Label, Multicenter, Basket Study Evaluating the Safety and Efficacy of Brexucabtagene Autoleucel in Adults with Rare B-cell … Ended

2022-501260-18-00 Relapsed/refractory Richter Transformation (RT) 4 2023-04-14
A Phase 2, Open-Label, Multicenter, Basket Study Evaluating the Efficacy of Brexucabtagene Autoleucel in Adults with Rare B-cell Malignancie… Ended

2022-501261-46-00 Relapsed/Refractory Burkitt Lymphoma (BL) 4 2023-04-14
A Phase 2, Open-Label, Multicenter, Basket Study Evaluating the Safety and Efficacy of Brexucabtagene Autoleucel in Adults with Rare B-cell … Ended

2022-501262-21-00 Relapsed/Refractory Hairy Cell Leukemia 4 2023-04-14
MK-4280A versus Physician’s Choice Chemotherapy in PD-(L)1-refractory, relapsed/refractory Classical Hodgkin Lymphoma Ended

2023-503615-14-00 Relapsed or Refractory Classical Hodgkin Lymphoma 4 2022-09-29
Safety and Efficacy Study of Pembrolizumab (MK-3475) as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy (MK-3… Ended

2022-501251-81-00 Renal cell carcinoma 5 2017-06-08
Pembrolizumab (MK-3475) and pembrolizumab in combination with other investigational agents in high risk NMIBC patients unresponsive to BCG Ended

2022-502526-41-00 Non-Muscle Invasive Bladder Cancer (NMIBC) 4 2016-03-15